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ABSTRACT 
Guanylyl cyclase C (GCC), the receptor for diarrheagenic bacterial enterotoxins (STs), 
inhibits colorectal cancer cell proliferation by co-opting Ca2+ as the intracellular 
messenger. Similarly, extracellular Ca2+ (Ca2+o) opposes proliferation and induces terminal 
differentiation in intestinal epithelial cells. In that context, human colon cancer cells 
develop a phenotype characterized by insensitivity to cytostasis imposed by Ca2+o. Here, 
preconditioning with ST, mediated by GCC signaling through cyclic nucleotide-gated 
channels, restored Ca2+o-dependent cytostasis, reflecting post-transcriptional regulation of 
Ca2+o-sensing receptors (CaRs). ST-induced GCC signaling deployed CaRs to the surface 
of human colon cancer cells, while elimination of GCC signaling in mice nearly abolished 
CaR expression in enterocytes. Moreover, ST-induced Ca2+o-dependent cytostasis was 
abrogated by CaR-specific antisense oligonucleotides. Importantly, following ST 
preconditioning, newly expressed CaRs at the cell surface represented tumor cell receptor 
targets for antiproliferative signaling by CaR agonists. Since expression of the endogenous 
paracrine hormones for GCC is uniformly lost early in carcinogenesis, these observations 
offer a mechanistic explanation for the Ca2+o-resistant phenotype of colon cancer cells. 
Restoration of antitumorigenic CaR signaling by GCC ligand replacement therapy 
represents a previously unrecognized paradigm for the prevention and treatment of human 
colorectal cancer employing dietary Ca2+ supplementation. 
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INTRODUCTION 
Colorectal cancer is most prevalent in the developed world, representing the second 
leading cause of cancer-related mortality (1,2). Although the epidemiology of this disease 
is poorly understood, there is an unexplained inverse relationship between the worldwide 
incidence of colorectal cancer and enterotoxigenic E. coli (ETEC) infections (3,4). ETEC 
produce heat-stable enterotoxins (STs), exogenous ligands for the intestine-specific 
receptor guanylyl cyclase C (GCC) (5) and a principle cause of secretory diarrhea in 
endemic populations and animal herds (6-8). Regions of the world with the highest 
incidence of ETEC-associated diarrhea exhibit the lowest incidence of colon cancer (4). In 
that context, activation of GCC inhibits human colon carcinoma cell proliferation (4,9,10) 
and adenoma formation in mice (3). 
Reduced expression of the endogenous paracrine hormones for GCC, guanylin and 
uroguanylin, represents an early mutational event in colorectal carcinogenesis (11-13). 
GCC signaling through its second messenger cGMP promotes fluid and electrolyte 
secretion (5), opposes cell cycle progression and proliferation (4,9), and regulates 
migration, differentiation and apoptosis along the crypt-villus axis (14,15). Importantly, 
targeted GCC deletion (GCC-/-) in mice increased intestinal tumorigenesis induced by the 
carcinogen azoxymethane or APC mutations by corrupting homeostatic crypt proliferation 
and genomic integrity (16). These observations suggest a model in which colorectal cancer 
is a disease of hormone insufficiency where dysregulation of GCC signaling, following 
loss of guanylin and uroguanylin, promotes tumorigenesis by disrupting mucosal 
homeostasis (16). However, beyond production of cGMP, molecular mechanisms by which 
GCC regulates processes underlying carcinogenesis remain undefined. 
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Like GCC, extracellular Ca2+ (Ca2+o) opposes proliferation and promotes differentiation of 
intestinal mucosa cells (17-20). Moreover, Ca2+ supplementation abrogates intestinal 
hyperproliferation and tumor formation induced by a Western-style diet in APCMin/+ mice 
(21). In part, these antitumorigenic effects may reflect GCC-induced activation of cyclic 
nucleotide-gated (CNG) channels, inducing cytostasis through Ca2+o influx (4). Notably, 
Ca2+o in the colonic lumen may increase to ≥20 mM which activates calcium-sensing 
receptors (CaRs) (19,22), G protein-coupled receptors (23) expressed in apical membranes 
of colonocytes (24), an event resulting in reduced proliferation and tumorigenesis through 
inhibition of β-catenin/Tcf-4 signaling, and increased cell maturation through p21 and p27 
activities (25,26). Conversely, Ca2+o supports colorectal cancer cell proliferation by 
capacitative entry through store-operated Ca2+ channels (SOCs) (27,28), which opposes 
antiproliferative GCC signaling through CNG and Ca2+o entry (28). Thus, opposing 
mechanisms regulating proliferative balance by Ca2+o comprise functional units 
reciprocally orchestrated in colon cancer cells (28). 
Here, the functional relationship between GCC and Ca2+o was explored in human colon 
carcinoma cells preconditioned with ST, in the context of a dynamic range of Ca2+o, and in 
GCC-/- mice. These studies revealed a previously unappreciated role for GCC in regulating 
CaR signaling, offering a novel paradigm for the prevention and treatment of human 
colorectal cancer employing hormone replacement therapy with GCC ligands in 
combination with oral Ca2+ supplementation. 
MATERIALS AND METHODS 
Tumor Cell Proliferation. Proliferation of cancer cells was quantified in 96 well/plates by 
[methyl-3H]thymidine (0.2 µCi/well) incorporation into DNA (9). Cells were pulse-labeled 
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(3 h) with 3H-thymidine at the end of 24 h periods of proliferation induced by 10 mM L-
glutamine. Following 3H-thymidine labeling, media was aspirated, cells were incubated for 
15 min with ice-cold 10% TCA and rinsed sequentially with 10% TCA and 100% 
methanol. The acid-insoluble material containing 3H-labeled DNA was solubilized in 100 
µL of 0.2 N NaOH, 80 µL aliquots were dissolved in 1 ml ScintiVerse and radioactivity 
quantified in a Packard β-scintillation spectrometer. All experiments were conducted on 
exponentially growing tumor cells. 
Tumor Cell Toxicity. Cytotoxicity, including occurrence of apoptosis or necrosis, was 
assessed by flow cytometry (9). Cancer cells (~106 cells per well in 6-well plates) were 
treated (24 h) with the indicated reagents. Then, cells were placed in suspension by 
trypsinization, pelleted by centrifugation, washed with PBS, and fixed in ice-cold 75% 
ethanol (30 min). After another wash with PBS, cells were resuspended in the staining 
solution (50 µg/mL propidium iodide, 100 µg/mL RNase A, 1 mM EDTA and 0.1% Triton 
X-100), and analyzed on a Coulter EPICS XL-MCL flow cytometer. Distribution in 
different phases of the cell cycle was analyzed using WinMDI software (version 2.8) 
provided by Joseph Trotter, Scripps Research Institute (La Jolla, CA). Twenty thousand 
cells, cleared from doublets, were analyzed from each sample. 
Cyclic GMP Assay. GCC-induced intracellular cGMP accumulation was assessed after 
treating cancer cells in triplicate with ST (15 min in 6 well/plates) employing Eagle’s 
minimal essential medium (EMEM) supplemented with 2 mM L-glutamine. Reactions 
were terminated by adding ice-cold 100% ethanol, each well was washed twice with ice-
cold 100% ethanol, and supernates separated from pellets by centrifugation (12,000 g, 15 
min at 4oC). Supernates containing cGMP were evaporated in a Savant SVC-100H 
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concentrator (Thermo Electron Corporation, Waltham, MA) and reconstituted with 50 mM 
sodium acetate (pH 4.0), and cGMP was quantified in each sample in triplicate by 
radioimmunoassay (4). 
Immunoblot analysis. Proteins from total cell lysates, cytosol or membrane extracts (28) 
prepared in SDS sample buffer were separated by electrophoresis on SDS-PAGE, 
transferred on nitrocellulose membranes, and then probed with rabbit polyclonal antibodies 
directed against CaR (dilution, 1:1,000) or human GAPDH (1:1,000), or with goat anti-
villin antibody [Villin(C-19); 1:1,000] in TBS-Tween (5% milk) overnight at 4°C. Then, 
membranes were probed with HRP-conjugated secondary antibody (dilution, 1:5,000) for 1 
h at room temperature, and specific bands were visualized employing West Pico 
Chemiluminescent Substrate and subjected to densitometry. Immunoblots, performed 
under reducing conditions, exhibited only 1 specific band of ~125 kDa corresponding to 
the monomer form of CaR. 
Immunostaining Analyses. For immunohistochemistry, tumor cells were washed 2 times 
with cold PBS and immediately fixed (30 min in 4% paraformaldehyde) at room 
temperature followed by quenching with 3% H2O2. CaR or CD104 at the cell surface were 
visualized employing (overnight at 4oC) rabbit anti-CaR (1:100) or mouse monoclonal 
anti-human CD104 (1:100), respectively, and the Histostain-plus kit. For 
immunofluorescence, GCC-/- mice, generated by neomycin-resistant gene insertion on an I-
129 background (29) and backcrossed with a C57BL/6 strain for ≥7 generations, were 
employed.  All animals were treated in compliance with the National Institute of Health 
Guidelines for the Care and Use of Laboratory Animals and under a protocol approved by 
the Institutional Animal Care and Use Committee of Thomas Jefferson University.  GCC+/+ 
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and GCC-/- littermates (males, 2 months old; N, 3 per genotype) were sacrificed, the 
intestine collected, divided into anatomically comparable segments and processed for 
paraffin-based archiving. Paraffin embedded tissue sections (5 μm) were rehydrated, 
heated (2 times for 5 min in citrate buffer, pH 6) for antigen retrieval, incubated overnight 
(4oC) with rabbit anti-CaR (1:100) or goat anti-villin (1:50) followed by incubation for 30 
min (room temperature) with Alexa fluor 555 anti-rabbit IgG (for CaR) or Alexa fluor 488 
anti-goat IgG (for villin). Digital images were acquired by computers attached to a light 
microscope or a confocal laser scanning microscope (LSM510, Carl Zeiss, Jena, 
Germany). 
Cell Transductions. A 5’ 327 bp CaR fragment containing 8 bp of upstream DNA was 
cloned into MSCV-puro retroviral vectors in both sense and antisense orientations (30), 
confirmed by DNA sequencing. Antisense, sense, and empty vectors were transfected 
along with the packaging vector pCL Ampho into HEK 293 cells employing Fugene. Viral 
supernatants harvested at 48 and 72 h after transfection were used to transduce T84 cells 
(for 72 h). Then, tumor cells stably transduced with CaR antisense, CaR sense or empty 
vector were selected employing 5μg/ml puromycin in DMEM/F12. 
Statistical analysis. Data are expressed as the mean ± SEM of a representative of at least 
three experiments performed in triplicate. Data were analyzed employing the unpaired two-
tailed Student’s t-test, and significance was assumed for p<0.05. 
RESULTS 
Colorectal Cancer Cells are Insensitive to Ca2+o-Dependent Cytostasis. While intestinal 
epithelial cells along the crypt-villus axis transition from proliferation to differentiation at 
lumenal Ca2+o ~2-3 mM (22), neoplastic transformation progressively desensitizes these 
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cells to the cytostatic effects of Ca2+o (20), with ultimate loss of Ca2+o-induced cell cycle 
arrest (31). Accordingly, Ca2+o induced cytostasis (Figure 1A), but not cytotoxicity (Figure 
1B), in moderately and well-differentiated colon cancer cells. However, Ca2+o failed to 
induce cell cycle arrest and a substantial proliferating cell population (~20-30%) persisted 
at 50 mM Ca2+o (Figure 1A), consistent with a phenotype of insensitivity to proliferative 
restriction by Ca2+o in human colon cancer cells. 
ST Potentiates Ca2+o-Dependent Cytostasis by Inducing GCC Signaling Through 
CNG Channels. Acute (3 h) ST exposure, which restricts cell cycle progression of colon 
cancer cells by activating GCC signaling (4,9), induced cytostasis which was additive with 
Ca2+o (Figure 1C1). Indeed, cytostasis induced by acute ST exposure was not altered by 
Ca2+o over a range of 1-50 mM (Figure 1C2), suggesting that the antiproliferative effects of 
ST and Ca2+o are mediated by distinct, non-interfering mechanisms. In contrast, ST 
preconditioning (24 h), which induces desensitization to GCC-dependent cytostasis in 
colon cancer cells (10), potentiated the inhibition of proliferation by Ca2+o (Figure 1C1). 
Thus, ST synergistically increased the potency (IC50: Ca2+o alone, 9.91 ± 1.09 mM; ST plus 
Ca2+o, 6.49 ± 1.13 mM) and efficacy (mean % proliferation: Ca2+o alone, 61.30 ± 1.84; ST 
plus Ca2+o, 49.47 ± 2.14) of Ca2+o to inhibit colon cancer cell proliferation (p < 0.001; 
Figure 1C1). Importantly, while failing to inhibit cell proliferation, reflecting 
desensitization to cGMP signaling (10) (see conditions at 1 mM Ca2+o in Figure 1C1), ST 
preconditioning revealed a novel antiproliferative mechanism which required ≥3 mM Ca2+o 
(Figure 1C2). 
Potentiation of Ca2+o-induced cytostasis by ST preconditioning was mediated by GCC, 
since ST, but not an inactive analog, inhibited (IC50, 62.22 ± 3.21 nM; Figure 2A) 
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proliferation of human colon carcinoma cells expressing GCC, but not of cells lacking 
GCC (32) (Figure 2B). Similarly, the effects of ST preconditioning were greater in T84 
cells, which exhibits the highest GCC expression (32), compared to Caco-2 cells (Figure 
2B). Further, two membrane-permeant cGMP analogs mimicked (Figure 2B), whereas an 
inhibitor of cyclic nucleotide-hydrolyzing phosphodiesterases enhanced (Figure 2C), the 
effects of ST preconditioning on tumor cell proliferation. Conversely, two inhibitors of 
CNG channels and an intracellular Ca2+ chelator, but not inhibitors of PKG or cAMP-
dependent protein kinase, blocked ST-mediated potentiation of Ca2+o-dependent cytostasis 
(Figure 2C). Notably, ST did not induce cytotoxicity in colon cancer cells exposed to high 
Ca2+o (Figure 2D). Rather, ST delayed the progression of these tumor cells through the cell 
cycle (Figure 2D), consistent with the notion that GCC agonists are cytostatic agents for 
colon cancer (4,9,10). Together, these observations suggest that in colon cancer cells 
induction of Ca2+o-dependent cytostasis by ST preconditioning is mediated by cGMP-
dependent activation of CNG channels and Ca2+o entry, the same effector mechanism 
mediating GCC-induced cell cycle delay (4). 
GCC Regulates the Function of CaRs in Normal and Malignant Colonocytes. 
Increased antiproliferative effects of Ca2+o following ST preconditioning did not reflect 
enhanced GCC-dependent cytostasis by Ca2+o, because increased Ca2+o did not enhance 
cytostasis induced by GCC signaling (+ST for 3 h in Figure 1C2) and did not prevent 
GCC-mediated desensitization in cGMP signaling (10) (Figure 3A). Rather, ST 
preconditioning enhanced Ca2+o-dependent cytostasis by coupling increased Ca2+o with 
intracellular signaling mechanisms induced by cGMP signaling (Figure 2A-C). Ca2+o 
induces cytostasis in colonocytes, in part, by activating CaR signaling (22), a mechanism 
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typically lost during neoplastic transformation (26,33). ST preconditioning (≥3 h) 
augmented the complement of total cellular (Supplementary Figure 1A) and membrane-
bound CaRs (Figure 3B) without significantly altering cytosolic CaRs (Figure 3B) or CaR 
mRNA levels (data not shown). Further, examination of specific cell fractions 
(Supplementary Figure 1B) revealed that ST treatment (3 h) induces ~80 fold increase of 
CaR at tumor cell membranes (Supplementary Figure 1C), reflecting translocation of 
~60% of the total complement of CaR protein in cancer cells from the cytosol to the 
membrane compartment (Supplementary Figure 1D). Importantly, GCC signal deprivation, 
either in ligand-free tumor cells (Figure 4, In Vitro panels on the left showing CaR surface 
staining of T84 cells) or in enterocytes of GCC-/- mice (Figure 4, In Vivo panels on the 
right), reduced CaRs in cell membranes. Induction of GCC signaling with bacterial 
enterotoxin in tumor cells or endogenous paracrine hormonal circuitry in enterocytes of 
GCC+/+ mice, in turn, increased the complement of CaRs at the cell surface (Figure 4). 
Effects of ST preconditioning on CaR staining at the surface of cancer cells were selective 
(Supplementary Figure 2), independent of elevated Ca2+o but dependent upon cGMP 
signaling through CNG (Figure 4). Moreover, compared to GCC+/+ mice, CaR expression 
in brush border membranes of GCC-/- enterocytes was uniformly attenuated along the 
entire rostrocaudal axis of the intestine in a GCC-specific fashion, since the expression of a 
marker for absorptive cells, villin, remained unchanged in the same anatomical locations 
(Figure 4, In Vivo panels showing representative sections from the jejunum). Thus, GCC 
signaling physiologically regulates post-transcriptional expression of CaRs in enterocytes, 
and ST preconditioning induces cell surface translocation of CaR receptors in human colon 
cancer cells. 
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ST Preconditioning, with Restoration of CaR Signaling, is a Novel Cytostatic 
Therapeutic Strategy in Colon Cancer Cells. To explore whether post-transcriptional 
regulation of CaRs mediates Ca2+o-dependent antiproliferation induced by ST 
preconditioning, CaR expression in colon cancer cells was eliminated employing specific 
antisense constructs (30) (Supplementary Figure 3; ~70% inhibition of CaR expression by 
densitometry, normalized to the respective GAPDH, in CaR antisense-transfected cells 
compared to CaR sense controls). While the response of tumor cells to Ca2+o was not 
altered by CaR antisense (Figure 5A), reflecting lack of effective CaR signaling in colon 
cancer cells, CaR antisense eliminated the response to Ca2+o of cancer cells preconditioned 
with ST (Figure 5B). Further, ST preconditioning of tumor cells produced a novel 
sensitivity of DNA synthesis to acute inhibition by 10 mM, but not 1 mM, Ca2+o 
(Supplementary Figure 4), consistent with membrane translocation of low-affinity CaRs 
which typically sense 3-10 mM Ca2+o (34). Moreover, beyond Ca2+o, other CaR agonists, 
including Mg2+, Gd3+ and spermine selectively inhibited proliferation of cancer cells 
preconditioned by ST (Figure 5C). Thus, ST preconditioning restores the sensitivity of 
human colon cancer cells to Ca2+o-dependent antiproliferation through CaRs, suggesting 
GCC-induced CaRs as previously unrecognized therapeutic targets for cytostatic strategies 
in patients with colorectal cancer. 
DISCUSSION 
Enterotoxins STs (18 amino-acid long) and endogenous paracrine hormones guanylin and 
uroguanylin (15/16 amino-acid long) are structurally homologous peptides (35,36), which 
specifically bind to and activate GCC at enterocyte brush-border membranes inducing 
PKG-dependent ion channel currents (36). In this way, endogenous hormones regulate 
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body fluid homeostasis, while STs, principle diarrheagenic agents maximally activating 
that pathway, permit enterotoxigenic bacteria to propagate in the environment (7,36-38). 
Of significance, GCC-/- mice exhibit increased proliferation, migration and apoptosis, and 
decreased differentiation along the crypt-villus axis (14), and are more susceptible to 
intestinal tumorigenesis induced by azoxymethane or APC mutations (16). Moreover, 
expression of guanylin and uroguanylin are uniformly lost early in intestinal 
carcinogenesis (11-13), loss of guanylin expression resulted in crypt hyperproliferation 
(15), and administration of GCC ligands inhibits intestinal tumor formation in APCmin/+ 
mice (3) and cell cycle progression of colon cancer cells (9). Thus beyond fluid 
homeostasis, GCC controls proliferation and tumorigenesis in intestine. 
Mechanisms mediating antiproliferation by GCC appear diverse. GCC signaling through 
unidentified effectors engages colonic cell quality control mechanisms assuring genomic 
integrity and tumor suppression (16). Also, GCC- and cGMP-dependent Ca2+ influx 
through CNGs induces colon cancer cell cytostasis by reducing nuclear rates of DNA 
synthesis (4,9). Here, a previously unappreciated mechanism contributing to tumor 
suppression by GCC is described (Figure 5D). ST preconditioning induces cGMP-
mediated CNG signaling, and synthesis and cell surface delivery of CaRs. Increased CaRs 
at the plasma membrane, in turn, provide new tumor-specific targets for antiproliferative 
signaling by CaR agonists, including Ca2+o, Mg2+, Gd3+ and spermine. Although mediated 
by the same proximal effector, Ca2+o influx through CNG, inhibition of DNA synthesis (4) 
and activation of CaR signaling (Figure 5D) represent two distinct, non-overlapping GCC-
dependent antiproliferative mechanisms, distinguished by acute (minutes) (9) and chronic 
(≥3 hr Figure 3B) kinetics, respectively. They may represent sequential temporal arms of 
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an integrated antiproliferative strategy in which acute cytostasis, silenced by 
phosphodiesterase-dependent desensitization of cGMP signaling (10), is propagated by 
CaR-dependent signaling to ensure enduring colon tumor cytostasis imposed by GCC. 
Interestingly, CaR signaling also promotes phosphodiesterase-dependent hydrolysis of 
cGMP (39), a mechanism that may contribute to desensitize cGMP-mediated inhibition of 
DNA synthesis and represents a negative feedback loop for cGMP-induced CaR. 
First discovered in parathyroid cells where it senses blood Ca2+ levels and regulates 
parathyroid hormone release (40), CaRs are expressed in many cell types, including 
osteoclasts, neurons and hematopoietic cells (23,41,42). In colonocytes, CaRs sense 1-10 
mM Ca2+o in fecal water by interacting with the amino-terminal extracellular domain, 
inducing intracellular signaling through heterotrimeric G proteins (23,43). One emerging 
function of CaRs in colonocytes is the regulation of proliferation and differentiation and its 
putative role as a tumor suppressor (22,24,44). Although the CaR gene is not lost or 
mutated in colon cancer (33), CaR expression is inexplicably reduced during disease 
progression (25,26,33). The present finding that GCC regulates the post-transcriptional 
expression of CaRs in normal and malignant intestinal cells offers a mechanistic 
explanation for that observation, since GCC signaling is silenced early during colorectal 
tumorigenesis following loss of ligand expression (11-13). Accordingly, elimination of 
GCC signaling in mice abolished the expression of CaRs in enterocytes (Figure 4). 
Moreover, CaRs are primarily expressed in the apex and central regions of human crypts 
(26) where expression of endogenous GCC ligands and cGMP levels are greatest (45,46), 
suggesting that CaR signaling may be conditionally regulated along the crypt-villus axis by 
GCC and cGMP-dependent mechanisms. In this model, the common abilities of CaRs and 
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GCC to promote the transition from proliferation to differentiation and inhibit intestinal 
carcinogenesis may represent convergent, rather than parallel, signaling pathway(s). 
Finally, although they remain to be fully characterized, GCC effects on CaRs, including 
induction of translation, post-translational processing or trafficking to cell membranes, 
represent a previously unrecognized mechanism of transcriptionally-independent 
regulation of CaR surface expression and signaling (47). 
Beyond CaR, Ca2+o opposes tumorigenesis by forming benign insoluble complexes with 
toxic ionized fatty acids and bile acids (48), and promoting cis-dimerization of E-cadherin 
molecules underlying cell-cell adhesion (49) and growth suppression (50). This latter 
mechanism, which occurs at Ca2+o >0.5 mM (49) and induces the function of p27 (50), 
may explain, in part, the cytostatic effects of high Ca2+o in colon cancer cells not exposed 
to ST observed here. Indeed, these cells were not affected by CaR antisense delivery 
(Figure 5A) or application of CaR agonists (Figure 5C), indicating that in the absence of 
GCC activation CaRs is functionally silent in colon cancer cells. Loss of GCC (11-13) and 
CaR (25,26,33) signaling, in turn, may underlie the resistant phenotype of colon cancer 
cells to Ca2+o-induced cytostasis (20,31). These observations are significant since levels of 
3-10 mM Ca2+o, required for significant CaR activation (34), are typically achieved in the 
fecal colonic water as a result of dietary Ca2+ intake, absorption, and secretion (19,22). 
Moreover, allosteric CaR activators present in the intestinal lumen such as L-amino-acids 
(23) may further increase the CaR sensitivity for Ca2+o. Importantly, CaRs sense other 
polyvalent cations (i.e., Gd3+, Mg2+, Ni2+, polylysine), including polyamines (spermine, 
spermidine and putrescine) endogenously produced by colonic bacteria (23), suggesting 
that GCC-induced CaRs may subserve diverse tumor suppressor pathways in intestine. 
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Strategies for cancer control include chemoprevention and chemotherapy. In contrast to its 
endogenous ligands, GCC is universally over-expressed in colorectal tumors (51,52), and 
oral administration of GCC ligands is a novel targeted approach to prevent tumor initiation 
and arrest disease progression in patients (3,4,9). Limitations to these therapies include 
adverse effects associated with the use of diarrheagenic bacterial enterotoxins (7,37,38). 
Conversely, dietary Ca2+ supplementation has been proposed as a chemoprevention 
strategy against colon cancer (53). However, caution has been suggested based on the 
reduced efficacy of Ca2+o to inhibit intestinal cell proliferation following neoplastic 
transformation, likely reflecting reduced CaR expression (33). In that context, dietary Ca2+o 
could potentially promote growth of Ca2+o-insensitive tumor cells while suppressing 
proliferation of normal adjacent cells, which retain Ca2+o sensitivity (22). The present 
observations that GCC preconditioning restores antitumorigenic CaR signaling in human 
colon carcinoma cells may offer a solution to the limitations of Ca2+o supplementation 
strategies. Oral Ca2+o therapy, in turn, may prevent adverse effects of GCC-targeted 
strategies because activation of CaR opposes secretory diarrhea by bacterial enterotoxins 
(39). Taken together, these data suggest that combinatorial therapies including dietary 
Ca2+o supplementation and GCC ligand replacement represent a previously unrecognized 
paradigm for the prevention and treatment of human colorectal cancer. 
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LEGENDS TO FIGURES 
Fig. 1.  Bacterial enterotoxin ST potentiates Ca2+o–mediated cytostasis in colorectal cancer 
cells. (A) Dose responses of cytostasis by Ca2+o in various human colon carcinoma cells. †, 
P < 0.01, versus control for Caco-2 cells; #, P < 0.05 and ##, P < 0.01, versus respective 
controls in each of the three cell lines. (B) Absence of cytotoxicity by Ca2+o in human 
colon cancer cells. Cytotoxicity was assessed as the proportion of tumor cells identified by 
flow cytometry in the sub-G1 fractions, which correspond to cells undergoing apoptosis or 
necrosis, of the cell cycle. Data are mean ± SEM from 3 independent experiments. (C1) 
Concentration dependence of T84 cell proliferation on Ca2+o in the presence or absence of 
1 μM ST. Results in (A) and (C1) are expressed as the percentage of respective control 
incubations treated with 1 mM Ca2+o. *, p<0.05 and **, P < 0.01, comparing respective 
conditions treated with Ca2+o alone and Ca2+o plus ST for 24 h. In (C2), data obtained in 
(C1) are expressed as {100-[(condition treated with ST plus Ca2+o)/(respective control 
condition treated with Ca2+o alone) x 100]}. 
Fig. 2.  ST potentiates Ca2+o–mediated cytostasis by inducing GCC signaling through 
CNG. (A) Dose response of ST-induced potentiation of antiproliferation by Ca2+o in T84 
cells. (B) ST (1 μM) actions on Ca2+o are mediated by GCC and cGMP in colorectal cancer 
cells. TJU, 1 μM of the inactive ST analog TJU 1-103; 8-br-cGMP (5 mM) and 8-pCPT-
cGMP (0.5 mM), membrane-permeant cGMP analogues. (C) CNG channel and Ca2+o entry 
are the proximal molecular effectors of enhanced Ca2+o cytostasis by ST (1 μM) in T84 
cells. IBMX (50 μM), the general phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine; L-DLT (L-cis-diltiazem, 10 μM) and PET (8-br-PET-cGMPS, 50 μM), 
two inhibitors of CNG channels; BAPTA (2 μM), the intracellular Ca2+ chelator BAPTA-
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AM; RP8pCPT (50 μM), the PKG inhibitor Rp-8-pCPT-cGMP; Rp-cAMPS (50 μM), an 
inhibitor of cAMP-dependent protein kinase. Inhibitors were employed at concentrations 
that completely inhibit their target enzymes (4). Results in (A) are expressed as the 
percentage of respective control incubations treated with 10 mM Ca2+o, while in (B) and 
(C) are expressed as in Figure 1c2. *, p<0.05 and **, P < 0.01, versus respective parallel 
control conditions treated with 10 mM Ca2+o. (D) ST (1 μM) induces cytostasis, but not 
cytotoxicity, in synchronized T84 cells exposed to 10 mM Ca2+o. The percentage of tumor 
cells in each phase of the cell cycle, including the sub-G1 fraction of apoptotic/necrotic 
cells, was quantified by flow cytometry. Data are from a representative experiment. 
Fig. 3.  ST induces CaR translocation in colon cancer cells. (A) Intracellular cGMP 
accumulation induced by ST (1 μM for 15 min) in T84 cells pre-treated with ST (1 μM for 
24 h) or the vehicle control in the presence of the indicated Ca2+o concentration. *, p<0.05, 
versus respective control conditions not pre-treated with ST. (B) Time-course of ST (1 
μM) effects on cytosol (upper panel) or membrane (lower panel) CaR expression in T84 
cells. PBS, the vehicle control; GAPDH and villin, the loading controls. 
Fig. 4.  Ligand-dependent GCC signaling upregulates surface CaR receptors in normal and 
transformed intestinal epithelial cells. Membranes of non-permeabilized T84 cells (In 
Vitro) were stained (brown) with specific rabbit polyclonal anti-CaR in the presence of low 
(0.5 mM; left column) or high (5 mM; right three columns) Ca2+o (magnification, 40X). In 
blue, counterstaining of nuclei with hematoxylin. Tumor cells were treated for 24 h with 
PBS (vehicle control; upper row), ST (1 μM; middle row) or 8-br-cGMP (5 mM; lower 
row), in the absence (left two columns) or presence (right two columns) of the indicated 
CNG inhibitors (see Figure 1 legend for keys). Also, epithelial cells in villus tips from the 
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jejunum of GCC+/+ and GCC-/- mice were stained with DAPI (blue, nuclei) and specific 
antibodies against villin (green, enterocyte brush-border membranes) and CaR (red), and 
subjected to confocal microscopy (magnification, 63X). 
Fig. 5.  CaR induced by ST is a novel therapeutic target in human colon cancer cells. (A 
and B) The proliferation of T84 cells stably expressing the empty vector (Vector, control), 
the CaR antisense vector (AS-CaR) or the CaR sense vector (S-CaR) was examined. Cells 
were treated for 24 h with Ca2+o (5 mM) alone (A) or ST (1 μM) plus Ca2+o (5 mM) (B). 
Results are expressed as in Figure 1c2; the controls were low (0.5 mM; A) or high (5 mM; 
B) Ca2+o. *, p<0.05, versus parallel control conditions. (C) T84 cell proliferation exposed 
to CaR agonists was measured as the percentage of respective control incubations treated 
with 0.5 mM Ca2+o (first two columns on the left). CaR agonists were added to tumor 
incubations for 24 h in the presence of the vehicle control (PBS) or ST (1 μM), and 
include: Ca2+, 10 mM; Mg2+, 20 mM; Gd3+, 100 μM, and spermine, 100 μM. CaR agonists 
are used at concentrations that maximally induce CaR signaling (34,40). *, p<0.05 and **, 
P < 0.01, versus respective control (PBS) conditions. (D) Proposed molecular mechanism 
for restoration of CaR signaling by GCC associated with colorectal cancer suppression (see 
Discussion for description). 
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